Grunenthal GmbH - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Grunenthal GmbH - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Grunenthal GmbH - Product Pipeline Review - 2015', provides an overview of the Grunenthal GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grunenthal GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Grunenthal GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Grunenthal GmbH's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Grunenthal GmbH's pipeline products

Reasons to buy

- Evaluate Grunenthal GmbH's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Grunenthal GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Grunenthal GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Grunenthal GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grunenthal GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Grunenthal GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Grunenthal GmbH Snapshot 6
Grunenthal GmbH Overview 6
Key Information 6
Key Facts 6
Grunenthal GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
Grunenthal GmbH - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Grunenthal GmbH - Pipeline Products Glance 14
Grunenthal GmbH - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Grunenthal GmbH - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Grunenthal GmbH - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Grunenthal GmbH - Unknown Stage Pipeline Products 19
Unknown Products/Combination Treatment Modalities 19
Grunenthal GmbH - Drug Profiles 20
cebranopadol 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
tapentadol hydrochloride 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule 1 for Pain 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule 2 for Pain 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
GRTTA-2210 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RO-656570 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule-3 for Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules for Inflammation 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule for Pain 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Activate KCNQ Channels for Chronic Pain and CNS disorder 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
lexanopadol 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Target KCNQ and TSPO for Pain 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Grunenthal GmbH - Pipeline Analysis 36
Grunenthal GmbH - Pipeline Products by Target 36
Grunenthal GmbH - Pipeline Products by Route of Administration 37
Grunenthal GmbH - Pipeline Products by Molecule Type 38
Grunenthal GmbH - Pipeline Products by Mechanism of Action 39
Grunenthal GmbH - Recent Pipeline Updates 40
Grunenthal GmbH - Dormant Projects 42
Grunenthal GmbH - Company Statement 43
Grunenthal GmbH - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Grunenthal GmbH, Key Information 6
Grunenthal GmbH, Key Facts 6
Grunenthal GmbH - Pipeline by Indication, 2015 8
Grunenthal GmbH - Pipeline by Stage of Development, 2015 10
Grunenthal GmbH - Monotherapy Products in Pipeline, 2015 11
Grunenthal GmbH - Partnered Products in Pipeline, 2015 12
Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2015 13
Grunenthal GmbH - Phase III, 2015 14
Grunenthal GmbH - Phase II, 2015 15
Grunenthal GmbH - Phase I, 2015 16
Grunenthal GmbH - Preclinical, 2015 17
Grunenthal GmbH - Discovery, 2015 18
Grunenthal GmbH - Unknown, 2015 19
Grunenthal GmbH - Pipeline by Target, 2015 36
Grunenthal GmbH - Pipeline by Route of Administration, 2015 37
Grunenthal GmbH - Pipeline by Molecule Type, 2015 38
Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2015 39
Grunenthal GmbH - Recent Pipeline Updates, 2015 40
Grunenthal GmbH - Dormant Developmental Projects,2015 42
Grunenthal GmbH, Other Locations 44
Grunenthal GmbH, Subsidiaries 45